You are here

J Clin Invest DOI:10.1172/JCI64801

2-Aminoadipic acid is a biomarker for diabetes risk.

Publication TypeJournal Article
Year of Publication2013
AuthorsWang, TJ, Ngo, D, Psychogios, N, Dejam, A, Larson, MG, Vasan, RS, Ghorbani, A, O'Sullivan, J, Cheng, S, Rhee, EP, Sinha, S, McCabe, E, Fox, CS, O'Donnell, CJ, Ho, JE, Florez, JC, Magnusson, M, Pierce, KA, Souza, AL, Yu, Y, Carter, C, Light, PE, Melander, O, Clish, CB, Gerszten, RE
JournalJ Clin Invest
Volume123
Issue10
Pages4309-17
Date Published2013 Oct
ISSN1558-8238
Keywords2-Aminoadipic Acid, Aged, Animals, Biomarkers, Blood Glucose, Case-Control Studies, Cell Line, Diabetes Mellitus, Type 2, Diet, High-Fat, Female, Homeostasis, Humans, Insulin, Insulin-Secreting Cells, Male, Metabolome, Mice, Mice, Inbred C57BL, Middle Aged, Organ Specificity, Reproducibility of Results, Risk, Tissue Culture Techniques
Abstract

Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic β cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans.

URLhttp://dx.doi.org/10.1172/JCI64801
DOI10.1172/JCI64801
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24091325?dopt=Abstract

Alternate JournalJ. Clin. Invest.
PubMed ID24091325
PubMed Central IDPMC3784523
Grant ListN01-HC-25195 / HC / NHLBI NIH HHS / United States
R01-DK-HL081572 / DK / NIDDK NIH HHS / United States
R01 HL081572 / HL / NHLBI NIH HHS / United States
/ / Canadian Institutes of Health Research / Canada
N01HC25195 / HL / NHLBI NIH HHS / United States